A5019581189- Cutaneous Melanoma Detection and Management
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Hepatocellular Carcinoma Treatment and Prognosis
- Testicular diseases and treatments
- Cervical Cancer and HPV Research
- Statistical Methods and Inference
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
- Chromatin Remodeling and Cancer
- Ocular Oncology and Treatments
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Ecology and Conservation Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Trauma and Emergency Care Studies
- Nonmelanoma Skin Cancer Studies
- Statistical Methods and Bayesian Inference
- Cancer-related molecular mechanisms research
- Renal and related cancers
- Meta-analysis and systematic reviews
University of Southern California
2017-2025
Children's Oncology Group
2019-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2025
University of Alberta
2024
Southern California University for Professional Studies
2023
Yanbian University
2021
Arcadia
2020
The University of Texas MD Anderson Cancer Center
2016-2018
The University of Texas Health Science Center at Houston
2015-2017
Dalian Minzu University
2014
The National Cancer Institute-Children's Oncology Group Pediatric MATCH trial aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts childhood and young adult patients with cancer by screening tumors for actionable alterations.
Abstract Background National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory solid tumors, brain lymphomas, and histiocytic disorders to phase II trials of molecularly targeted therapies based on detection predefined genetic alterations. Patients whose tumors harbored EZH2 mutations or loss SMARCB1 SMARCA4 by immunohistochemistry were treated inhibitor tazemetostat. Methods received tazemetostat...
To prospectively determine the prevalence of high-risk histopathologic features (HRFs) in patients with unilateral retinoblastoma who undergo enucleation and to evaluate role chemotherapy preventing recurrences.Children newly diagnosed enucleated were enrolled prospectively. After central histopathology review, specific HRFs received chemotherapy; others observed. Primary end points event-free survivals (EFS).Of 331 during 2005 2010, 321 eligible had review. Discordance between review...
The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies of molecularly targeted therapies on the basis detection predefined genetic alterations. Patients tumors harboring mutations fusions driving activation mitogen-activated protein kinase (MAPK) pathway were treated MEK inhibitor selumetinib.
Metastatic retinoblastoma has a poor prognosis when treated with conventional chemotherapy and radiation therapy (RT). Intensified may improve the outcome.A prospective, international trial enrolled patients extraocular retinoblastoma. Patients stage II or III (locoregional) received four cycles of chemotherapy, followed by involved field RT (45 Gy). IVa IVb (metastatic trilateral) also those ≥ partial response then one cycle high-dose carboplatin, thiotepa, etoposide autologous...
Abstract Purpose Treatment outcomes for hepatoblastoma have improved markedly in the contemporary treatment era, principally due to therapy intensification, with overall survival increasing from 35% 1970s 90% at present. Unfortunately, these advancements are accompanied by an increased incidence of toxicities. A detailed analysis age as a prognostic factor may support individualized risk‐based stratification. Methods We evaluated 1605 patients included CHIC database assess relationship...
Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) germ cell tumor (GCT) pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine serum assay minimal residual setting we compared raw (Cq) and normalized (∆Cq, RQ) values from prior assays, validated interlaboratory concordance by aliquot swapping. Revised was determined a cohort 32 patients suspected retroperitoneal disease. Assay superiority comparing resulting...
648 Background: MicroRNAs (mi-RNAs) have emerged as promising biomarkers for the detection of viable germ cell tumors (GCT). Our previous work in a research lab demonstrated optimal performance with positive results that had Cq values less than 28, an indeterminate range between 28-35 and negative greater 35. In this study, we assessed characteristics miR-371a-3p CLIA certified at UCSD. Methods: Due to workflows, equipment scaling, several modifications were required from our original...
Abstract Externally controlled trials have commonly been used when conducting a randomized trial (RCT) is not feasible or ethical. By allowing the study of new treatments, use external controls can lead to accelerated advances in management rare diseases. The controls, however, introduces challenges due potential differences between population are enrolled from and patients on from. Some include, but limited to, how diagnosed treated, case mix underlying populations, ability measure...
The International Prognostic Scoring System-Revised (IPSS-R) is one standard for myelodysplastic syndrome (MDS) risk stratification. It divides patients into five categories including an intermediate subset (IPSS-R int-risk). Outcomes and clinical interventions with IPSS-R int-risk are not well defined. We performed analysis of outcomes this group patients. Out 3167 patients, a total 298 were identified MDS retrospectively analyzed to assess characteristics affecting outcomes. Cox...
10011 Background: The screening protocol for the NCI-Children’s Oncology Group (COG) Pediatric Molecular Analysis Therapy Choice (MATCH) trial detects tumor alterations that are used to assign patients with treatment-refractory or recurrent cancers phase 2 treatment arms of molecularly-targeted therapies. Methods: Patients age 1 21 years old solid tumors, non-Hodgkin lymphomas, histiocytic disorders treated at U.S. based COG sites eligible. DNA and RNA extracted from FFPE samples sequenced...
Background The Children's Oncology Group (COG) adopted cisplatin, 5‐flourouracil, and vincristine (C5V) as standard therapy after the INT‐0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin doxorubicin. Subsequent experience demonstrated doxorubicin to be effective patients recurrent disease C5V, this suggested that it could incorporated intensify for advanced disease. Methods In nonrandomized, phase 3 COG trial, primary aim was explore...
10009 Background: The NCI-Children’s Oncology Group (COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) trial assigns patients, age 1-21 years, with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase 2 treatment arms based on genetic alterations detected in their tumor. Arm C evaluated the EZH2 inhibitor tazemetostat patients whose tumors harbored hotspot mutations SMARCB1 SMARCA4 loss by immunohistochemistry. Methods: Tazemetostat 1200 mg/m /dose PO...
10007 Background: The NCI-Children’s Oncology Group (COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) trial assigns patients aged 1-21 years with relapsed or refractory solid tumors, CNS lymphomas, and histiocytic disorders to phase 2 treatment arms of molecularly-targeted therapies based on genetic alterations in their tumor. Arm B (APEC1621B) evaluated the orally bioavailable FGFR inhibitor erdafitinib whose tumors harbored activating 1/2/3/4. Methods: Patients received oral...
3009 Background: The NCI-Children’s Oncology Group (COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) trial assigns patients age 1 to 21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders phase 2 treatment arms of molecularly-targeted therapies based on genetic alterations detected in their tumor. Arm J evaluated the ERK1/2 inhibitor ulixertinib (BVD-523FB) whose tumors harbored activating MAPK pathway ( ARAF, BRAF, HRAS, KRAS, NRAS, MAPK1,...
The National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial enrolled children aged 1-21 years with treatment-refractory solid tumors and predefined actionable genetic alterations. Patients harboring alterations in DNA damage repair (DDR) genes were assigned to receive olaparib.
This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, selective oral inhibitor BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring mutations.